# Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin

Study · id `cardio:ct-nct01990469` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01990469](<https://clinicaltrials.gov/study/NCT01990469>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01990469

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 219 participants.

## Technical summary

Registry record NCT01990469. Randomized; quadruple masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2015-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 219 participants (enrolled count; ClinicalTrials.gov record NCT01990469, source copy `cardio:ctgov-nct01990469-2016-04-19`, retrieved 2026-10-26)
- Start date: 2014-01 (registry gives no type) (ClinicalTrials.gov record NCT01990469, source copy `cardio:ctgov-nct01990469-2016-04-19`, retrieved 2026-10-26)
- Primary completion: 2015-04 (actual) (ClinicalTrials.gov record NCT01990469, source copy `cardio:ctgov-nct01990469-2016-04-19`, retrieved 2026-10-26)
- Completion: 2015-04 (actual) (ClinicalTrials.gov record NCT01990469, source copy `cardio:ctgov-nct01990469-2016-04-19`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01990469-2016-04-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin
- Condition: T2DM
- Intervention (Drug): Gemigliptin
- Intervention (Drug): Gemigliptin placebo
- Lead sponsor: LG Life Sciences
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: LG Life Sciences (`cardio:org-lg-life-sciences`)

## Provenance

Content hash: 6cb8338d650471f2a4e7f040fa86b21cae189019f971e7fc7c873f1bb0a9dc82
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
